Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present DBV Technologies S.A. (NASDAQ: DBVT).

Full DD Report for DBVT

You must become a subscriber to view this report.


Recent News from (NASDAQ: DBVT)

DBV Technologies reports 1H results
DBV Technologies (NASDAQ: DBVT ): 1H GAAP EPS of -€2.60. More news on: DBV Technologies, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: September, 07 2018 05:43
DBV Technologies : Reports First Half 2018 Financial Results
DBV Technologies Reports First Half 2018 Financial Results DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2018 financial results. The interim financial report is available on the ...
Source: Thomson Reuters ONE
Date: September, 07 2018 01:30
Intrommune advancing peanut allergy candidate, pre-IND meeting with FDA completed
Privately held Intromune Therapeutics met recently with the FDA to discuss the details of an IND for INT301, an immunotherapy to treat peanut allergy. Once approved, clinical studies may begin. More news on: AnaptysBio, Aimmune Therapeutics, DBV Technologies, Healthcare stocks news, ...
Source: SeekingAlpha
Date: September, 06 2018 11:15
DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the ECI
   DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the European Congress of Immunology PARIS, GENEVA and BANGKOK September 5, 2018 - DBV ...
Source: Thomson Reuters ONE
Date: September, 05 2018 01:30
Investor Expectations to Drive Momentum within Mazor Robotics, Kinross Gold, Mimecast, DBV Technologies S.A., Adamas Pharmaceuticals, and Adverum Biotechnologies - Discovering Underlying Factors of Influence
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mazor Robotics Ltd. (NASDAQ:MZOR), Kinross Gold Corporation (NYSE:KGC), M...
Source: GlobeNewswire
Date: August, 20 2018 08:25
Aimmune And DBV Technologies: A Comparison
Last year, I was quietly rooting for DBV technologies ( DBVT ) mainly because they are an European company relatively less known in the US, thus offering a solid diversification avenue. However, trial results have shown that Aimmune ( AIMT ) is probably the better drug, and although the news i...
Source: SeekingAlpha
Date: August, 13 2018 03:59
DBV Technologies Reports June 30, 2018 Cash Position
DBV Technologies Reports June 30, 2018 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced its cash and cash equivalents as of June 30, 2018. Cash and cash equivalents: Cash and cash equivalents as of June 30, 2018, we...
Source: Thomson Reuters ONE
Date: July, 27 2018 01:30
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer Demonstrated track record of success instrumental in preparing for potential Viaskin Peanut launch in 2019 DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinic...
Source: Thomson Reuters ONE
Date: July, 26 2018 01:30
DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel
DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel Shareholders approve all proposed resolutions DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq St...
Source: Thomson Reuters ONE
Date: June, 22 2018 16:00
Aimmune Therapeutics: Special Situation Biotech Opportunity
Overview: Millions of Americans suffer from food allergies, with peanut allergy being the most popular among those. Aimmune's CODIT (Characterized Oral Desensitization ImmunoTherapy) therapy is designed to be a one-time series of treatments that raises a patient's tolerance of peanuts enou...
Source: SeekingAlpha
Date: June, 08 2018 12:24

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0821.3021.8822.0621.29567,102
2018-05-1725.1624.7925.2624.7388,695
2017-02-0333.6033.4233.8233.40274,517
2017-02-0234.1933.9334.4733.9335,750
2017-02-0134.1634.4534.4534.0342,799

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1452,78978,76667.0200Short
2018-12-1340,68674,90754.3154Short
2018-12-1254,517103,14352.8557Short
2018-12-1116,92325,91065.3146Short
2018-12-1037,31845,74881.5730Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DBVT.


About DBV Technologies S.A. (NASDAQ: DBVT)

Logo for DBV Technologies S.A. (NASDAQ: DBVT)

Not available

 

Contact Information

 

 

Current Share Structure

  • Issue and Outstanding: 49,981,644 - 12/31/2017

 


Recent Filings from (NASDAQ: DBVT)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 16 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 08 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: April, 12 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 03 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 26 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 23 2018

 

 


Daily Technical Chart for (NASDAQ: DBVT)

Daily Technical Chart for (NASDAQ: DBVT)


Stay tuned for daily updates and more on (NASDAQ: DBVT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: DBVT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DBVT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of DBVT and does not buy, sell, or trade any shares of DBVT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/